Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: SarcomaNCT ID: NCT02106312
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:
To study the feasibility of reducing the dose of preoperative radiotherapy in MLS (Myxoid Liposarcomas) from 50 Gy to 36 Gy while maintaining comparable clinicopathological responses.
Conducting Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital
Overall PI: Elizabeth Baldini, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: Thomas DeLaney, MD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
Andrew Crocker, 617-525-8099,
firstname.lastname@example.orgMassachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100